GlaxoSmithKline (GSK) Given a GBX 1,775 Price Target at Goldman Sachs Group

GlaxoSmithKline (LON:GSK) has been assigned a GBX 1,775 ($24.89) price objective by equities researchers at Goldman Sachs Group in a research note issued on Thursday. The brokerage presently has a “buy” rating on the stock. Goldman Sachs Group’s price target points to a potential upside of 37.49% from the stock’s current price.

Other equities analysts have also issued research reports about the stock. Beaufort Securities reiterated a “buy” rating and set a GBX 1,800 ($25.24) price target on shares of GlaxoSmithKline in a report on Monday, October 23rd. Liberum Capital reiterated a “buy” rating and set a GBX 1,760 ($24.68) price target on shares of GlaxoSmithKline in a report on Wednesday, October 25th. Jefferies Group lifted their price target on shares of GlaxoSmithKline from GBX 1,675 ($23.49) to GBX 1,700 ($23.84) and gave the stock a “buy” rating in a report on Monday, October 16th. set a GBX 1,925 ($26.99) price target on shares of GlaxoSmithKline and gave the stock a “buy” rating in a report on Thursday, October 26th. Finally, Berenberg Bank dropped their target price on shares of GlaxoSmithKline from GBX 1,835 ($25.73) to GBX 1,760 ($24.68) and set a “buy” rating on the stock in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. GlaxoSmithKline has an average rating of “Hold” and an average target price of GBX 1,541.36 ($21.61).

Shares of GlaxoSmithKline (GSK) traded down GBX 12.80 ($0.18) during trading hours on Thursday, hitting GBX 1,291 ($18.10). 11,680,000 shares of the stock were exchanged, compared to its average volume of 9,480,000. The firm has a market capitalization of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($17.32) and a 52 week high of GBX 1,724.50 ($24.18).

In other news, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Also, insider Sir Roy Anderson bought 562 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were acquired at an average cost of GBX 1,278 ($17.92) per share, with a total value of £7,182.36 ($10,070.61). Over the last three months, insiders have bought 581 shares of company stock valued at $743,284.

TRADEMARK VIOLATION NOTICE: “GlaxoSmithKline (GSK) Given a GBX 1,775 Price Target at Goldman Sachs Group” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/11/glaxosmithkline-gsk-given-a-gbx-1775-price-target-at-goldman-sachs-group.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply